Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia

Erna Kristin, Dwi Endarti, Levina Chandra Khoe, Kartika Widayati Taroeno-Hariadi, Christina Trijayanti, Armansyah Armansyah, Sudigdo Sastroasmoro

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Since 2016, bevacizumab has been widely used to treat metastatic colorectal cancer (mCRC) in Indonesia. Nevertheless, the high cost of bevacizumab has raised the question of whether the therapy is considered cost-effective and should be included in the national health insurance system. This study aimed to assess the cost-effectiveness of bevacizumab plus chemotherapy versus chemotherapy alone for the treatment of mCRC patients. Methods: A Markov model was applied using the perspective of the Indonesian healthcare system to assess cost-effectiveness. The health outcomes were expressed in terms of quality-adjusted life years (QALY) using the validated EuroQoL-5D-5L instrument. Data for medical costs were collected from hospital billings in four hospitals located in three different cities in Indonesia. Meanwhile, data for utility were obtained from interviewing 90 patients who came to the hospital. We compared those mCRC patients who received chemotherapy alone either with FOLFOX or FOLFIRI, versus patients who received the addition of bevacizumab. Results: With the perspective of societal, the incremental cost-effectiveness ratio (ICER) of adding bevacizumab was USD 49,312 per QALY gained using secondary data and USD 28,446 per QALY using real world data. Conclusion: Using either a healthcare or societal perspective, the addition of bevacizumab for mCRC treatment was considered not cost-effective.

Original languageEnglish
Pages (from-to)1921-1926
Number of pages6
JournalAsian Pacific Journal of Cancer Prevention
Volume22
Issue number6
DOIs
Publication statusPublished - Jun 2021

Keywords

  • Metastatic colorectal cancer- bevacizumab- chemotherapy

Fingerprint

Dive into the research topics of 'Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia'. Together they form a unique fingerprint.

Cite this